Credit Suisse analyst Robert Spingarn recommends using the pullback in shares of TransDigm Group (TDG) following Citron Research's negative report as a buying opportunity. Any government pursuit of lower prices would likely be a lengthy process, Spingarn tells investors in an intraday research note. He notes the comparison to Valeant Pharmaceuticals (VRX) is nothing new. The analyst also sees a low likelihood of President Trump tweeting about TransDigm. Spingarn has an Outperform rating on the shares with a $297 price target. The supplier of aircraft components is down 10%, or $24.75, to $227.09 in afternoon trading.